A Safety Study of 3 Different Bowel Cleansing Preparations

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01501513
Recruitment Status : Completed
First Posted : December 29, 2011
Last Update Posted : July 15, 2014
Information provided by (Responsible Party):
Braintree Laboratories

Brief Summary:
The objective of this study is to compare the safety, tolerance and efficacy of BLI800 (approved and investigational regimens) to an approved control preparation as bowel preparations prior to colonoscopy in adult patients, particularly including the elderly and those with renal and/or hepatic impairment.

Condition or disease Intervention/treatment Phase
Colonoscopy Bowel Preparation Endoscopy Drug: PEG-3350 based bowel preparation Drug: BLI800 approved preparation regimen Drug: BLI800 investigational preparation regimen Phase 3

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 540 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Safety, Tolerance and Efficacy Evaluation of 3 Different Bowel Cleansing Preparations in Adult Subjects, Including the Elderly and Subjects With Hepatic or Renal Insufficiency
Study Start Date : December 2011
Actual Primary Completion Date : April 2013

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Colonoscopy

Arm Intervention/treatment
Experimental: BLI800 approved preparation regimen
BLI800 approved preparation regimen
Drug: BLI800 approved preparation regimen
solution for oral administration prior to colonoscopy

Experimental: BLI800 investigational preparation regimen
BLI800 investigational preparation regimen
Drug: BLI800 investigational preparation regimen
solution for oral administration prior to colonoscopy

Active Comparator: PEG-3350 based bowel preparation
PEG-3350 based bowel preparation
Drug: PEG-3350 based bowel preparation
solution for oral administration prior to colonoscopy

Primary Outcome Measures :
  1. Frequency of adverse events [ Time Frame: 6 months ]

Secondary Outcome Measures :
  1. % of subjects with successful preparation [ Time Frame: Day of colonoscopy ]
    rated by blinded colonoscopist on 4 point scale (1 = poor to 4 = excellent)

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Male or female outpatients who are undergoing colonoscopy for a routinely accepted indication.
  • At least 18 years of age
  • If female, and of child-bearing potential, is using an acceptable form of birth control
  • Negative urine pregnancy test at screening, if applicable
  • In the Investigator's judgment, subject is mentally competent to provide informed consent to participate in the study

Exclusion Criteria:

  • Subjects with known or suspected ileus, severe ulcerative colitis, gastrointestinal obstruction, gastric retention, bowel perforation, toxic colitis or megacolon.
  • Subjects who had previous significant gastrointestinal surgeries.
  • Subjects who have uncontrolled clinically significant pre-existing electrolyte disturbances.
  • Subjects with severe liver or renal insufficiency.
  • Subjects with a history of congestive heart failure or other clinically significant cardiac abnormality.
  • Subjects with impaired consciousness that predisposes them to pulmonary aspiration.
  • Subjects undergoing colonoscopy for foreign body removal and decompression.
  • Subjects who are pregnant or lactating, or intending to become pregnant during the study.
  • Subjects of childbearing potential who refuse a pregnancy test.
  • Subjects allergic to any preparation components
  • Subjects who, in the opinion of the Investigator, should not be included in the study for any reason, including inability to follow study procedures.
  • Subjects who have participated in an investigational surgical, drug, or device study within the past 30 days.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01501513

United States, Alabama
University of South Alabama
Mobile, Alabama, United States, 36693
United States, California
Advanced Clinical Research Institute
Anaheim, California, United States, 92801
United States, Florida
Mayo Clinic Jacksonville
Jacksonville, Florida, United States, 32224
Borland-Groover Clinic
Jacksonville, Florida, United States, 32256
Miami Research Associates
South Miami, Florida, United States, 33143
United States, Indiana
Indiana University
Indianapolis, Indiana, United States, 46202
United States, Louisiana
Delta Research Partners
Monroe, Louisiana, United States, 71201
United States, Massachusetts
Commonwealth Clinical Studies
Brockton, Massachusetts, United States, 02302
United States, Mississippi
Gastrointestinal Associates
Jackson, Mississippi, United States, 39202
United States, North Carolina
Asheville Gastroenterology Associates
Asheville, North Carolina, United States, 28801
Carolina Digestive Health Associates
Charlotte, North Carolina, United States, 28262
Wake Research Associates
Raleigh, North Carolina, United States, 27612
United States, Ohio
Consultants for Clinical Research
Cincinnati, Ohio, United States, 45219
United States, Oregon
Northwest Gastroenterology
Portland, Oregon, United States, 97210
United States, Tennessee
Chattanooga, Tennessee, United States, 37421
Franklin Gastroenterology
Franklin, Tennessee, United States, 37067
United States, Virginia
Charlottesville Medical Research
Charlottesville, Virginia, United States, 22911
Sponsors and Collaborators
Braintree Laboratories

Responsible Party: Braintree Laboratories Identifier: NCT01501513     History of Changes
Other Study ID Numbers: BLI800-440
First Posted: December 29, 2011    Key Record Dates
Last Update Posted: July 15, 2014
Last Verified: July 2014

Keywords provided by Braintree Laboratories:
bowel preparation

Additional relevant MeSH terms:
Polyethylene glycol 3350
Gastrointestinal Agents